secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001193125-25-154057
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics prices $200M public offering of 24.2M shares at $8.25/share
-----------------------------------------------------------------------------

- Gross proceeds of $200M; net proceeds ~$187M ($215.2M if underwriters exercise 30-day option for 3.6M additional shares).
- Closing expected July 2, 2025; all shares sold by the company, resulting in dilution.
- Cash runway extended into Q3 2027 inclusive of June 2025 $100M term loan from Hercules Capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525154057/0001193125-25-154057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525154057/d38498d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-154057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer